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Immune dysregulation during deep space missions has the capacity 
to synergize with other variables such as oxidative damage or 
radiation exposure.   This would further enhance clinical risk to 
crewmembers. 
CYTOKINE NETWORK 




•Cell Mediated ‘Inflammatory’ Response 
•Fight intracellular pathogens (viruses) 
•Control DTH response to skin viral/bacterial 
antigens 
•Fight tumor formation 
•Phagocyte dependent inflammation   
 
Disease correlations:  
Rheumatoid arthritis 
organ specific immune disorders 
Chohn’s disease 
Sarcoidosis 
Acute allograft rejection 
Unexplained recurrent abortions 
Multiple sclerosis 




•Humoral (Antibody) Responses 





Disease correlations:  
Rapid progression of HIV to AIDS 
Chronic graft vs. host disease 
Systemic autoimmune diseases 
Atopic asthma 
Scleroderma 
































IFNg, IL-2, TNFa, LT
Purpose:  CMI, DTH, intracel lular pathogens .  Pro inflammatory, cause 
organ seci fic auto-immunity.
TGFb+IL-6 Th17
(Neutrophil. Inf.)
IL-17a, f, IL-21, IL-22
Purpose:  clear gut bacteria , other pathogens  not handled by Th1/2 
(ci trobacter,k. pheumoniae, candida).  Disease:  arthri ti s , MS, 





IL-4, IL-5 (IL-10, 9, 12)
Purpose:  humoral  immunity, extracel lular organisms.  Disease:  
a l lergy, atopy.  
TGFb + IL-4 Th9 IL-9, IL-10
IL-9 s timulates  prol i feration, prevents  apoptos is .  Effector subset (not 
regulatory subset).  Subset of Th2? Plastic, can switch to Th1 or Th17. 
TGFb Treg TGFb
Natura l ' Tregs  control  inflammation, secrete anti -inflammatory 
cytokines .  Reduced Treg function associated with many autoimmune 
disorders .  Express  CD25,CD152, icFoxp3.  
TGFb+IL-27 Tr1 IL-10, TGFb (IL-21 autoc)
Tregulatory type 1 cel l :  potent immunosuppress ive properties , do not 
express  Foxp3.  Main tolerance, control  autoimmunity, prevent graft 
rejection, GVH disease
Th3 TGFb, IL-10
Th3 cel l s  are involved in mucosal  immunity.  Mediate non 
inflammatory environment.  Promote switch to IgA (non-inflamm, does  
not activate c', not involved with phagocytos is )  Respons ible for 'ora l  
tolerance'?
IL-21 Tfh IL-6, IL-10, IL-21
Fol icular helper T cel l s .  Regulate s tep-wise development of ag-





•Determine the in-flight status of immunity, physiological stress, viral immunity/reactivation.    
•Specific measurements include leukocyte distribution, T cell function, cytokine production 
profiles (mRNA, intracellular, secreted, plasma), virus-specific T cell number/function, 
latent herpesvirus reactivation, stress hormone levels.  
•Determine the clinical risk related to immune dysregulation for exploration class 
spaceflight, as well as an appropriate monitoring strategy for spaceflight-associated 
immune dysfunction, that could be used for the evaluation of countermeasures. 
Specific Study Objectives 
Determine the nutritional status of astronauts before, during, and after spaceflight ensure 
adequate intake of energy, protein, and vitamins during missions.  
 
The Clinical Nutritional Status Assessment measures dietary intake, body composition, 
protein, bone, iron, mineral, vitamin, and antioxidant status (60 total analytes). Currently, 
it is a medical requirement for U.S. crewmembers on-board the ISS.  
 
The results of data analysis are used both to understand the connections between 
nutrition and human health during space flight, and to develop effective dietary strategies 
to reduce adverse health impacts (including bone loss, loss of important vitamins and 





























FGF basic CCL3/MIP-1 alpha 




For a 22-cytokine array, assuming a qualitative data, 
there are 4,194,304 possible outcomes. 
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•In general, levels of inflammatory and adaptive immunity cytokines are not 
elevated during long-duration spaceflight.   
 
•Reduced T cell, granulocyte, NK and monocyte function have all been 
reported following both long and short duration spaceflight, however no 
systemic inflammatory or adaptive immune activation evident during 
spaceflight.   
 
•Increases in growth factors and chemokines may indicate other types of 
adaptation occurring during spaceflight, such as attempts to overcome 
diminished immunocyte function. 
•Are there localized inflammatory processes 
that result in a downstream peripheral 
manifestation (IL-1ra, CXCL5, IL-8)? 
 
•There appear to be varied individual crew 
responses, and specific relationships between 
cytokines and markers of iron status and muscle 
turnover that warrant further evaluation.    
Conclusions 
